Envoy Medical, Inc. filings document a hearing-health company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record covers operating results, financial-condition updates, registration statements for securities offerings, warrant and pre-funded warrant structures, and disclosures related to its status as an emerging growth company.
Company filings also include proxy materials for director elections, auditor ratification, executive compensation, equity incentive and employee stock purchase plan amendments, and Nasdaq share-issuance approvals. Form 8-K disclosures address material agreements, auditor changes, compensatory arrangements, Nasdaq listing compliance, and risk-related matters such as going-concern language in audit reports.
Envoy Medical, Inc. has regained compliance with the Nasdaq Capital Market’s continued listing standards. Nasdaq confirmed that the company now meets Listing Rule 5550(b)(2) after previously receiving a notice in February 2025 for not maintaining the required $35 million Market Value of Listed Securities.
The company attributes its renewed compliance to strategic financing initiatives that substantially strengthened its balance sheet and will remain under a one-year discretionary panel monitor starting February 12, 2026. Envoy Medical states it believes it has an achievable plan to stay in compliance and continue trading on Nasdaq under the symbol COCH.
Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 812,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 187,500 shares.
Potashnick Robert reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 552,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 127,500 shares.
Kantor Susan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 249,990 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 57,690 shares.
BRYNELSEN CHARLES reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 2,600,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 600,000 shares.
Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 162,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 37,500 shares.
TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 48,750,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 11,250,000 shares.
Envoy Medical stockholder Glen A. Taylor filed an amended Schedule 13D to update his ownership after a February 2026 investment. He purchased 18,750,000 shares of Class A Common Stock together with Series A-1 Warrants for 11,250,000 shares and Series A-2 Warrants for 18,750,000 shares at a combined price of $0.40 per share and accompanying warrants, for an aggregate $7,500,000 funded with personal funds.
The common warrants have a $0.40 exercise price and become exercisable after stockholder approval of the warrant share issuance, with Series A-1 Warrants expiring up to 24 months after that approval (or earlier upon Milestone 1) and Series A-2 Warrants up to 60 months (or earlier upon Milestone 2). As of February 12, 2025, he is treated as beneficially owning 68,909,614 shares of Class A Common Stock, or 84.8% of the class, based on 76,881,110 shares outstanding immediately following the company’s offering, including the warrant shares. On the same date, he directly holds 29,040,049 outstanding shares, or 37.7% of those outstanding shares.
Envoy Medical, Inc. completed an upsized public offering that raised approximately $30.0 million in gross proceeds by selling an aggregate of 75,000,000 shares of Class A common stock (or pre-funded warrants in lieu) plus milestone-linked Series A-1 and Series A-2 warrants to purchase up to 120,000,000 additional shares.
The warrants carry a $0.40 exercise price and become exercisable after stockholder approval, with earlier expirations tied to FDA milestones for the company’s Acclaim cochlear implant. If fully exercised for cash, the warrants could bring in about $48.0 million more. Envoy plans to use the net proceeds for working capital and to fund its pivotal FDA clinical study, and it expects the financing to extend its cash runway into the second half of 2027.